Pemafibrate

Unassigned

New Medicines

Prevention of major cardiovascular events in patients with type 2 diabetes mellitus with dyslipidaemia

Information

New molecular entity
Kowa
Kowa

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective peroxisome proliferator-activated receptor-α modulator (SPPARM-α), taken twice daily [2].
There is a strong correlation between cardiovascular disease (CVD) and diabetes. At least 68% of people age 65 or older with diabetes die from some form of heart disease; and 16% die of stroke. Adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes [1].
Prevention of major cardiovascular events in patients with type 2 diabetes mellitus with dyslipidaemia
Oral